A prospective study of the LMB regimen for diffuse large cell non Hodgkin's lymphoma in adults

Leukemia and Lymphoma

Volumn 36, Issue 5-6, 2000, Pages 525-532

  Voog, E ^a   Sebban, C ^a   Biron, P ^a   Philip, T ^a   Blay, J Y ^a  

^a CENTRE LÉON BÉRARD   (France)

Author keywords

Chemotherapy; Diffuse large cell lymphoma; International prognostic index; LMB regimen; Survival

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FOLINIC ACID; HYDROCORTISONE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FOLLOW UP; HUMAN; INFECTION; LARGE CELL LYMPHOMA; MALE; NEPHROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SEPTIC SHOCK; THROMBOCYTOPENIA;

EID: 0033976786     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190009148400     Document Type: Article

References (22)

1. Fischer R.I., Gaynor E.R., Dahlberg S. (1993). Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-hodgkin's lymphoma. New England Journal of Medicine 328: 1002-6.
2. Miller TP, Dahlberg S, Cassady JR, et al. (1998). Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma. N Engl J Med 339: 21-6.
3. Wolf M, Matthews JP, Stone J, Cooper IA, Robertson TI, Fox RM. (1997). Long-term survival advantage of MACOP-B over CHOP in intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. Ann Oncol 8 (Suppl 1): 71-75.
4. Coiffier B. (1995). Fourteen years of high-dose CHOP (ACVB regimen): preliminary conclusions about the treatment of aggressive-lymphoma patients. Ann Oncol 6: 211-7.
5. Shipp MA, Neuberg D, Janicek M, Canellos GP, Shulman LN. (1995). High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. J Clin Oncol 13: 2916-23.
6. Haioun C, Lepage E, Gisselbrecht C, et al. (1997). Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 15: 1131-7.
7. Gianni AM, Bregni M, Siena S. et al. (1997). High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336:1290-7.
8. Verdonck LF, van Putten WL, Hagenbeek A, et al. (1995). Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 332: 1045-51.
9. Reyes F, Lepage E, Morel P, et al. (1997). Failure of first line inductive high dose chemotherapy in poor risk patients with agressive lymphoma: updated results of the randomized LNH93-3 study. Blood 90: 594a (abstract 2640).
10. Patte C., Philip T., Rodary C., et al. (1991). High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvment with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomised trial of 216 children. J. Clin. Oncol. 9: 123-132.
11. Patte C., Michon J., Bouffet E., et al. on behalf of the SFOP. (1992). High survival rates of childhood B-cell lymphoma and leukemia as results of the LMB89 protocol. Proc Am Assoc. Clin. Oncol. 11:340 (abstract 1164).
12. Patte C., Michon J., Behrendt C, et al. on behalf of the SFOP. (1992). B cell large cell lymphoma of children: description and outcome when treated with the same regimen as Burkitt. Ann.Oncol 7 (suppl. 3); 29 (abstract 092).
13. Philip T. Meckenstock R., Deconnick E., et al. (1992). Treatment of poor prognosis Burkitt's lymphoma in adults with the Societé Française d'Oncologie Pédiatrique LMB protocol. A study of the Fédération Nationale des Centres de Lutte contre le Cancer. Eur.J. Cancer 28A: 1954-1959.
14. Soussain C., Patte C., Ostronoff M., et al. (1995). Small non-cleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 86: 664-674.
15. Blay, JY., Bouhour, D., Carrie, C. et al. (1995). The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression. Blood 86: 2922-2929.
16. Kaplan EL., Meyer P (1958). Non parametric estimation from incomplete observations. J.Am. Stat. Assoc. 53: 457-81.
17. Shipp, M.A., Harrington, D.P., Anderson, JR. (1993). for the International Non-Hodgkin's Lymphoma Prognostic Factors Project. et al. A predictive model for aggressive NHL. N.Engl.J.Med 329: 987-994.
18. Philip T, Guglielmi C, Hagenbeek A, et al. (1995). Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-5.
19. Miller TP, Dana BW, Weick JK, et al. (1988). Southwest Oncology Group clinical trials for intermediate-and high-grade non-Hodgkin's lymphomas. Semin Hematol 25 (Suppl 2): 17-22.
20. JY Blay, D. Louis, E. Bouffet, et al. (1991). Management of Pediatric non Hodgkin's lymphoma. Blood Reviews 5: 90-97.
21. Shipp MA., Yeap BY., Harrington DP et al. (1990). The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the complete trial and comparison with the M-BACOD regimen. J. Clin. Oncol. 8: 84-93.
22. Longo DL., DeVita VT., Jr, Duffey PL et al. (1991). Superiority of ProMACE-CytaBOM in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomised trial. Journal of Clinical Oncology 9: 25-38.